The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Matthias, Oelze ^a   Swenja, Kröller Schõ N ^a   Philipp, Welschof ^a   Thomas, Jansen ^a   Michael, Hausding ^a   Yuliya, Mikhed ^a   Paul, Stamm ^a   Michael, Mader ^a   Elena, Zinßius ^a   Saule, Agdauletova ^a   Anna, Gottschlich ^a   Sebastian, Steven ^a   Eberhard, Schulz ^a   Serge, P Bottari ^b   Eric, Mayoux ^c   Thomas, Münzel ^a   Andreas, Daiber ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIV GRENOBLE ALPES   (France)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; EMPAGLIFLOZIN; GLUCOSE; HYDROETHIDINE; MESSENGER RNA; PHORBOL ESTER; STREPTOZOCIN; ZYMOSAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; GLUCOSE BLOOD LEVEL; GLUCOTOXICITY; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; MALE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET CELL; PHENOTYPE; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; VASCULAR DISEASE; WESTERN BLOTTING;

RATTUS;

EID: 84911942671     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112394     Document Type: Article

References (50)

1. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653.
2. Jay D, Hitomi H, Griendling KK (2006) Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med 40: 183-192.
3. Hink U, Li H, Mollnau H, Oelze M, Matheis E, et al. (2001) Mechanisms Underlying Endothelial Dysfunction in Diabetes Mellitus. Circ Res 88: E14-E22.
4. Wenzel P, Daiber A, Oelze M, Brandt M, Closs E, et al. (2008) Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis 198: 65-76.
5. Wenzel P, Schulz E, Oelze M, Muller J, Schuhmacher S, et al. (2008) AT1- receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 45: 619-626.
6. Schuhmacher S, Oelze M, Bollmann F, Kleinert H, Otto C, et al. (2011) Vascular Dysfunction in Experimental Diabetes Is Improved by Pentaerithrityl Tetranitrate but not Isosorbide-5-Mononitrate Therapy. Diabetes 60: 2608-2616.
7. Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, et al. (2003) Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J Biol Chem 278: 44719-44726.
8. Loot AE, Schreiber JG, Fisslthaler B, Fleming I (2009) Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 206: 2889-2896.
9. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, et al. (2002) Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51: 3274-3282.
10. Yamamoto Y, Yamagishi S, Yonekura H, Doi T, Tsuji H, et al. (2000) Roles of the AGE-RAGE system in vascular injury in diabetes. Ann N Y Acad Sci 902: 163-170; discussion 170-162.
11. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, et al. (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20: 742-752.
12. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, et al. (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280: E685-694.
13. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404: 787-790.
14. Schulz E, Wenzel P, Munzel T, Daiber A (2014) Mitochondrial redox signaling: Interaction of mitochondrial reactive oxygen species with other sources of oxidative stress. Antioxid Redox Signal 20: 308-324.
15. Kroller-Schon S, Steven S, Kossmann S, Scholz A, Daub S, et al. (2014) Molecular mechanisms of the crosstalk between mitochondria and NADPH oxidase through reactive oxygen species-studies in white blood cells and in animal models. Antioxid Redox Signal 20: 247-266.
16. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, et al. (2011) Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 124: 1370-1381.
17. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, et al. (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306: F188-193.
18. Evans JL, Goldfine ID (2013) Aging and insulin resistance: just say iNOS. Diabetes 62: 346-348.
19. Sarashina A, Koiwai K, Seman LJ, Yamamura N, Taniguchi A, et al. (2013) Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. Drug Metab Pharmacokinet 28: 213-219.
20. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, et al. (2013) A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 15: 721-728.
21. Hansen HH, Jelsing J, Hansen CF, Hansen G, Vrang N, et al. (2014) The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves beta-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat. J Pharmacol Exp Ther 350: 657-664.
22. Luippold G, Klein T, Mark M, Grempler R (2012) Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type1 diabetes mellitus. Diabetes Obes Metab 14: 601-607.
23. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, et al. (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14: 83-90.
24. Vickers SP, Cheetham SC, Headland KR, Dickinson K, Grempler R, et al. (2014) Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes 7: 265-275.
25. Oelze M, Knorr M, Schuhmacher S, Heeren T, Otto C, et al. (2011) Vascular dysfunction in streptozotocin-induced experimental diabetes strictly depends on insulin deficiency. J Vasc Res 48: 275-284.
26. Oelze M, Kroller-Schon S, Steven S, Lubos E, Doppler C, et al. (2013) Glutathione Peroxidase-1 Deficiency Potentiates Dysregulatory Modifications of Endothelial Nitric Oxide Synthase and Vascular Dysfunction in Aging. Hypertension.
27. Daiber A, Oelze M, Coldewey M, Bachschmid M, Wenzel P, et al. (2004) Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates. Mol Pharmacol 66: 1372-1382.
28. Kroller-Schon S, Knorr M, Hausding M, Oelze M, Schuff A, et al. (2012) Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 96: 140-149.
29. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, et al. (2006) Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension 48: 677-684.
30. Shiryaeva YK, Krylin VV, Titov VN (2012) Chromatographic determination of methyl glyoxal in blood plasma as the test for glycotoxicity and accumulation of glycation end-products. Bull Exp Biol Med 153: 114-117.
31. Wenzel P, Hink U, Oelze M, Seeling A, Isse T, et al. (2007) Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice. Brit J Pharmacol 150: 526-533.
32. Hausding M, Jurk K, Daub S, Kroller-Schon S, Stein J, et al. (2013) CD40L contributes to angiotensin II-induced pro-thrombotic state, vascular inflammation, oxidative stress and endothelial dysfunction. Basic Res Cardiol 108: 386.
33. Pricci F, Leto G, Amadio L, Iacobini C, Cordone S, et al. (2003) Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. Free Radic Biol Med 35: 683-694.
34. Yu Y, Lyons TJ (2005) A lethal tetrad in diabetes: hyperglycemia, dyslipidemia, oxidative stress, and endothelial dysfunction. Am J Med Sci 330: 227-232.
35. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, et al. (2014) Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124: 499-508.
36. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, et al. (2014) Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care 37: 1480-1483.
37. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, et al. (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13: 28.
38. Bierhaus A, Fleming T, Stoyanov S, Leffler A, Babes A, et al. (2012) Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 18: 926-933.
39. Sun M, Yokoyama M, Ishiwata T, Asano G (1998) Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. Int J Exp Pathol 79: 207-222.
40. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91: 7742-7746.
41. Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, et al. (2009) Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocininduced diabetic rats. Am J Nephrol 29: 274-282.
42. Kumar S, Prasad S, Sitasawad SL (2013) Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats. PLoS One 8: e67009.
43. Chen Z, Zhang J, Stamler JS (2002) Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A 99: 8306-8311.
44. Sydow K, Daiber A, Oelze M, Chen Z, August M, et al. (2004) Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113: 482-489.
45. Oelze M, Knorr M, Schell R, Kamuf J, Pautz A, et al. (2011) Regulation of human mitochondrial aldehyde dehydrogenase (ALDH-2) activity by electrophiles in vitro. J Biol Chem 286: 8893-8900.
46. Wenzel P, Hink U, Oelze M, Schuppan S, Schaeuble K, et al. (2007) Role of reduced lipoic acid in the redox regulation of mitochondrial aldehyde dehydrogenase (ALDH-2) activity. Implications for mitochondrial oxidative stress and nitrate tolerance. J Biol Chem 282: 792-799.
47. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, et al. (2008) Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321: 1493-1495.
48. Wang J, Wang H, Hao P, Xue L, Wei S, et al. (2011) Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol Med 17: 172-179.
49. Osar Z, Samanci T, Demirel GY, Damci T, Ilkova H (2004) Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus. Exp Diabesity Res 5: 155-162.
50. Chang FY, Shaio MF (1995) Respiratory burst activity of monocytes from patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 29: 121-127.